PRIVILEGED AND CONFIDENTIAL ATTORNEY-CLIENT PRIVILEGE / ATTORNEY WORK PRODUCT
March 30, 2024
C&H Matter Number: 1018-00009
UPDATED FIN 48 / ASC 740-10 RESERVE ANALYSIS — POST-SETTLEMENT
Prepared By:
Calderwood & Harkness LLP 1735 Market Street, Suite 3100 Philadelphia, PA 19103
Leonard Cross, Partner (Responsible Partner) Garrett Simmons, Associate (Lead Associate)
Prepared For:
Marcus Whitfield, Vice President of Global Tax Penterra Pharmaceuticals Corp.
Deborah Staines, General Counsel Penterra Pharmaceuticals Corp.
Rajesh Iyer, Chief Financial Officer Penterra Pharmaceuticals Corp.
Re: Final FIN 48 / ASC 740-10 Uncertain Tax Position Reserve Analysis Following IRS Appeals Settlement — Penterra Pharmaceuticals Corp. (EIN 22-3741856), Tax Years 2017–2020
Supersedes:
(1) Initial FIN 48 Reserve Analysis dated September 20, 2022
(2) Updated FIN 48 Analysis — Post-NOPA dated November 20, 2023
Right-click to update Table of Contents
I. Executive Summary
The purpose of this memorandum is to provide our final legal analysis under Accounting Standards Codification Topic 740-10, Income Taxes (formerly FASB Interpretation No. 48, "FIN 48") regarding the appropriate uncertain tax position ("UTP") reserve for Penterra Pharmaceuticals Corp. ("PPC" or the "Company") following the execution of an IRS Appeals settlement on March 29, 2024. This memorandum supersedes and replaces our prior analyses dated September 20, 2022 (Initial FIN 48 Reserve Analysis) and November 20, 2023 (Updated FIN 48 Analysis — Post-NOPA), to the extent they are inconsistent with the conclusions set forth herein. All prior analyses should be read in conjunction with, and as updated by, this memorandum.
Key Conclusion. Based upon our analysis of the settlement terms, the applicable legal authorities, and the continuing risk profile of PPC's intercompany transfer pricing arrangements, we conclude that PPC's UTP reserve related to its Irish IP-holding structure should be reduced from the pre-settlement level of $62.4 million to $14.8 million, effective as of the settlement date. This reduction reflects the conclusive resolution of the IRS examination for Tax Years 2017 through 2020 and our assessment of the remaining uncertain tax positions for open and future tax years (TY 2021 forward).
Settlement Summary. On March 29, 2024, PPC and the Internal Revenue Service executed IRS Form 906, Closing Agreement on Final Determination Covering Specific Matters, conclusively resolving all transfer pricing issues arising from the IRS examination of PPC's federal income tax returns for Tax Years 2017 through 2020. The principal terms of the settlement are as follows:
• Total settlement adjustment: $47.6 million across TY 2017–2020, representing approximately 12.51% of the IRS's proposed adjustment of $380.4 million.
• Federal income tax due: $10.0 million (computed at the 21% corporate tax rate applied to the $47.6 million adjustment).
• Estimated underpayment interest: Approximately $2.84 million, computed at the applicable federal underpayment rate under IRC § 6621 from the original due dates of the respective returns through the anticipated settlement payment date.
• IRC § 6662(e) penalty: Fully abated. The IRS Appeals Officer accepted PPC's reasonable-cause defense and contemporaneous transfer pricing documentation as establishing penalty protection under IRC § 6662(e)(3)(B).
• Total cash cost to PPC from the examination: Approximately $12.84 million (tax plus interest).
In addition to the direct tax and interest costs, PPC has incurred professional fees of approximately $8.33 million in connection with the examination and settlement, consisting of: Calderwood & Harkness LLP fees of $5,837,420; Whitmore Valuation Group LLC fees of $2,146,800; and Thornbury & Keogh (Dublin) fees of approximately €312,500 (~$341,200 at the average exchange rate). When professional fees are included, the total cost of the examination to PPC is approximately $21.17 million.
The settlement outcome is highly favorable to PPC. The IRS had proposed adjustments totaling $380.4 million, which would have resulted in additional federal income tax of approximately $79.88 million plus a substantial valuation misstatement penalty of approximately $15.98 million, for a total potential exposure (before interest) of approximately $95.86 million. The actual settlement at $12.84 million (tax plus interest) represents an approximate savings of $83.02 million, or an 86.6% reduction from the IRS's proposed assessment.
Intended Use. This memorandum is intended for use by PPC management and the Company's independent auditor, Crestfield & Associates LLP (Martin Ogilvy, Engagement Partner), in connection with PPC's financial statement reporting for the fiscal year ending December 31, 2024, and any restated or adjusted reporting for prior periods that may be required. This memorandum is protected by the attorney-client privilege and the attorney work product doctrine, and its distribution should be limited to the persons and entities identified herein, as authorized by PPC.
II. Background and Procedural History
A. PPC's Irish IP-Holding Structure
Penterra Pharmaceuticals Corp. is a Delaware corporation headquartered in Princeton Junction, New Jersey. PPC is a publicly traded pharmaceutical company listed on the Nasdaq Stock Market under the ticker symbol "PPCA." For its fiscal year ended December 31, 2020, PPC reported consolidated revenue of approximately $6.82 billion and consolidated pre-tax income of approximately $1.47 billion.
PPC maintains an international corporate structure through which it conducts its non-Americas pharmaceutical operations. The relevant entities in this structure, for purposes of the transfer pricing issues at issue in the IRS examination, are as follows:
Penterra Holdings Luxembourg S.à r.l. ("PHL"). PHL is a Luxembourg-organized société à responsabilité limitée with its registered office at 14 rue Aldringen, L-1118 Luxembourg (RCS No. B 168452). PHL is a wholly owned subsidiary of PPC and is treated as a disregarded entity for U.S. federal income tax purposes. PHL serves as a holding company and conduit in the overall corporate structure.
Penterra Biopharma International DAC ("PBI"). PBI is an Irish designated activity company with its registered office at Claremont House, Sandyford Business Park, Dublin D18 K7T4, Ireland (Irish Tax Reference No. 3218764T). PBI is a wholly owned subsidiary of PHL (and thus, for U.S. tax purposes, a wholly owned subsidiary of PPC's disregarded Luxembourg entity). PBI was incorporated on March 15, 2012 and commenced operations shortly thereafter. PBI is the principal operating entity for PPC's pharmaceutical business outside the Americas, holding rights to develop and exploit PPC's pharmaceutical intellectual property in those markets.
Penterra Manufacturing Ireland Ltd. ("PMI"). PMI is an Irish limited company (CRO No. 512347) located in Ringaskiddy, County Cork, Ireland. PMI operates as a contract manufacturer for PBI under a cost-plus arrangement, pursuant to which PMI is compensated at cost plus a markup of 8% for its contract manufacturing services. PMI's operations are not a direct subject of the IRS examination but are relevant context to PBI's overall functional profile.
Cost-Sharing Arrangement. PBI entered into a qualified cost-sharing arrangement ("CSA") with PPC, effective July 1, 2012. Under the CSA, PBI acquired rights to develop and exploit PPC's pharmaceutical intellectual property outside the Americas in exchange for two forms of consideration: (a) a platform contribution transaction ("PCT") payment of $312 million, representing compensation for the value of PPC's pre-existing intellectual property made available to PBI as of the CSA's effective date; and (b) ongoing cost-sharing payments calculated based on PBI's share of reasonably anticipated benefits from the intangible development activity, consistent with the requirements of Treasury Regulations § 1.482-7.
Legacy IP License. In addition to the CSA, PBI holds a separate license from PPC covering certain pre-2012 pharmaceutical compounds that were developed prior to PBI's formation and that are not subject to the CSA. Under this legacy license agreement, PBI pays a royalty of 4.5% on non-Americas net sales of the licensed compounds to PPC.
PBI's Substantive Operations. PBI maintains substantive pharmaceutical operations in Ireland, a fact that was central to PPC's defense in the IRS examination. As of 2020, PBI employed 185 individuals (up from 52 at its inception in 2012), maintained approximately 18,000 square feet of office space, and conducted 42 board meetings during the TY 2017–2020 period. PBI incurred cumulative regulatory expenditures of €47.2 million during the relevant period and maintained independent pricing authority across 68 country markets in its territory. PBI's management team includes individuals with significant pharmaceutical industry experience who exercise meaningful decision-making authority over the development, enhancement, maintenance, protection, and exploitation ("DEMPE") functions related to PPC's pharmaceutical intangibles in PBI's territory.
Key Products. The principal pharmaceutical products relevant to the transfer pricing analysis are:
• Veritaxol (oncology): Global revenue of $3.12 billion in 2020, of which $1.34 billion was attributable to non-Americas markets within PBI's territory.
• Imvara (immunology): Global revenue of $1.87 billion in 2020, of which $0.79 billion was attributable to non-Americas markets.
• Cerulon (rare disease): Global revenue of $0.62 billion in 2020, of which $0.28 billion was attributable to non-Americas markets.
PBI Financial Summary. For its fiscal year ended December 31, 2020, PBI reported revenue of approximately €2.14 billion and pre-tax income of approximately €1.06 billion. PBI's Irish effective tax rate was 12.5% on standard trading income, with a reduced rate of 6.25% applicable to qualifying income under Ireland's Knowledge Development box ("KDB") regime, which PBI has claimed with respect to eligible income since fiscal year 2016.
B. IRS Examination History
The IRS opened an examination of PPC's federal income tax returns (Forms 1120) for Tax Years 2017, 2018, 2019, and 2020 on May 16, 2022, as indicated by IRS Letter 2205-A issued to PPC on that date. The examination was conducted by the Large Business and International Division ("LB&I"), Northeast Transfer Pricing Practice, under Examination Team Identification Number LB&I-NE-TP-2022-00641.
The principal IRS personnel assigned to the examination were:
• Supervisory Revenue Agent: Gerald Meskill
• Lead Revenue Agent: Patricia Dunleavy
• IRS Economist: Dr. Alan Washburne
• IRS Chief Counsel Attorney-Advisor: Franklin Rosario
• Senior Counsel: Donna Hirabayashi
PPC was not enrolled in the IRS Compliance Assurance Process ("CAP") for the tax years at issue and did not have a bilateral advance pricing agreement ("APA") or any other pre-filing agreement covering the relevant transfer pricing positions.
During the course of the examination, the IRS issued forty-seven (47) Information Document Requests ("IDRs") between June 2022 and September 2023. These IDRs covered a wide range of topics, including PPC's corporate structure, the CSA and PCT documentation, transfer pricing economic analyses, PBI's functional and risk profiles, the legacy IP license, PBI's financial statements, board minutes, employee records, regulatory filings, and comparable company data.
Engagement of Calderwood & Harkness. PPC retained Calderwood & Harkness LLP to represent it in the IRS examination pursuant to an engagement letter executed on June 2, 2022. IRS Form 2848, Power of Attorney and Declaration of Representative, was filed on June 8, 2022, designating Leonard Cross (Partner), Katherine Hartwell (Of Counsel), Garrett Simmons (Associate), and Farzan Nazari (Associate) as PPC's authorized representatives.
Engagement of Whitmore Valuation Group. Whitmore Valuation Group LLC was retained under a Kovel arrangement to provide independent economic and valuation analysis in support of PPC's transfer pricing positions. The Kovel engagement letter, dated June 20, 2022 (reference 1018-00009-KV), established the engagement under the direction of Calderwood & Harkness to preserve the attorney-client privilege over the economists' work. Dr. Helena Vasquez served as the lead economist, with support from Dr. Rohan Chakrabarti.
C. IRS Proposed Adjustments (NOPA — October 12, 2023)
On October 12, 2023, the IRS issued a Notice of Proposed Adjustment ("NOPA") covering all four tax years under examination. The NOPA set forth four categories of proposed adjustments to PPC's reported taxable income, as described below.
Category 1 — CSA Cost-Sharing Ratio Adjustments. The IRS proposed increasing PBI's cost-sharing percentages under the CSA by approximately 8 to 12 percentage points for each of the examined years, on the ground that PBI's share of reasonably anticipated benefits was understated. The IRS's proposed adjustments and the underlying research and development expenditure base were as follows:
Category 2 — Royalty Rate Adjustment on Legacy IP License. The IRS proposed increasing the royalty rate on the legacy IP license from PPC's arm's-length rate of 4.5% to 11.0%, based on an alternative comparable uncontrolled transaction ("CUT") analysis prepared by Dr. Washburne. The resulting adjustments were:
The declining trajectory of the royalty adjustment reflects the decreasing sales of the legacy pre-2012 compounds over the examination period, consistent with product lifecycle expectations.
Category 3 — Correlative Offset. The IRS allowed a correlative offset of ($42.65 million) to avoid double-counting between the CSA cost-sharing adjustments and the royalty rate adjustments, recognizing the economic interrelationship between the two adjustments.
Category 4 — Economic Substance Challenge. The IRS raised an economic substance challenge to PBI's operations. However, this challenge was subsumed within the adjustments described in Categories 1 and 2 above and did not result in a separate quantified adjustment. The economic substance issue was raised primarily as a supporting theory for the transfer pricing adjustments.
Net Proposed Adjustment. The total net proposed adjustment across all four tax years was $380.40 million, computed as follows:
CSA cost-sharing ratio adjustments: $235.01M Royalty rate adjustments: $188.04M Correlative offset: ($42.65M) Net proposed adjustment: $380.40M
Proposed Penalty. The IRS also proposed an IRC § 6662(e) penalty for substantial valuation misstatement, computed at 20% of the underpayment attributable to the proposed adjustments. The estimated penalty was approximately $15.98 million ($380.4M × 21% tax rate × 20% penalty rate).
30-Day Letter. The IRS issued a 30-Day Letter on November 8, 2023, providing PPC with the opportunity to file a Protest and request consideration by the IRS Office of Appeals.
D. PPC Defense and Appeals Resolution
Formal Protest. Calderwood & Harkness, on behalf of PPC, filed a formal written Protest with the IRS on December 22, 2023, contesting all proposed adjustments and the proposed penalty. The Protest set forth PPC's factual and legal arguments in detail, supported by extensive economic analysis from Whitmore Valuation Group and contemporaneous transfer pricing documentation prepared by Crestfield & Associates LLP (Susan Lam, Transfer Pricing Partner).
Assignment to Appeals. The case was assigned to IRS Appeals Officer Noreen Castañeda in January 2024. Appeals Officer Castañeda is an experienced Appeals Officer within the LB&I Appeals function with substantial expertise in international transfer pricing matters.
Appeals Conference. An in-person Appeals conference was held on February 28, 2024, at the IRS Appeals Office in Manhattan, New York. The following individuals attended:
Calderwood & Harkness LLP: Leonard Cross (Partner), Katherine Hartwell (Of Counsel), Garrett Simmons (Associate)
Penterra Pharmaceuticals Corp.: Marcus Whitfield (VP, Global Tax), Deborah Staines (General Counsel)
Whitmore Valuation Group LLC: Dr. Helena Vasquez (Lead Economist)
Internal Revenue Service: Noreen Castañeda (Appeals Officer)
Key Defense Elements. PPC's defense centered on the following principal arguments and supporting evidence:
1. Contemporaneous Transfer Pricing Documentation. PPC maintained comprehensive contemporaneous transfer pricing documentation for all relevant intercompany transactions during TY 2017–2020, prepared by Crestfield & Associates (Susan Lam, Transfer Pricing Partner). This documentation was prepared on a timely basis and met the requirements of Treasury Regulations § 1.482-7 (for the CSA) and § 1.482-4 (for the legacy IP license), as well as the penalty protection requirements of IRC § 6662(e)(3)(B).
2. Whitmore CUT Analysis. Dr. Vasquez of Whitmore Valuation Group prepared a comprehensive comparable uncontrolled transaction analysis supporting PPC's 4.5% royalty rate on the legacy IP license. The analysis identified 14 comparable license agreements, with an interquartile range ("IQR") of 3.1% to 6.8% and a median of 4.4%. PPC's 4.5% royalty rate fell within the IQR and was closely aligned with the median, providing strong support for the arm's-length nature of the rate. The Whitmore analysis demonstrated significant flaws in the IRS's CUT analysis, including the use of non-comparable transactions involving different therapeutic areas, different stages of development, and different geographic scope.
3. CPM/TNMM Analysis. Whitmore also prepared a comparable profits method / transactional net margin method analysis identifying 22 comparable companies, demonstrating that PBI's profit margins fell within the IQR in all four examined years. This analysis provided corroborative support for the arm's-length nature of the overall intercompany arrangements.
4. PCT discounted Cash Flow Valuation. Whitmore's discounted cash flow analysis of the PCT payment supported a valuation range of $278 million to $361 million, using a weighted average cost of capital ("WACC") of 9.8%. PPC's actual PCT payment of $312 million fell within this range. The IRS had used a WACC of 7.2%, which Whitmore demonstrated was inappropriately low given the risk profile of early-stage pharmaceutical development.
5. Functional Analysis of PBI's DEMPE Functions and Economic Substance. Calderwood & Harkness and Whitmore prepared a detailed functional analysis demonstrating PBI's significant contributions to the development, enhancement, maintenance, protection, and exploitation of PPC's pharmaceutical intangibles in non-Americas markets. This analysis emphasized PBI's substantial headcount growth (from 52 to 185 employees), its €47.2 million in regulatory expenditures, its 42 board meetings, its independent pricing authority across 68 markets, and the qualifications and experience of its management team. This analysis directly rebutted the IRS's economic substance challenge.
Settlement. Following the Appeals conference, Appeals Officer Castañeda communicated a proposed settlement offer to Calderwood & Harkness on March 15, 2024. After careful analysis and discussion with PPC management, PPC accepted the proposed settlement on March 22, 2024. The acceptance was approved by PPC management, including Rajesh Iyer (CFO) and Richard Falk (VP, Finance).
The IRS Form 906, Closing Agreement on Final Determination Covering Specific Matters, was executed on March 29, 2024. The principal settlement terms are as follows:
Total Settlement Adjustment: $47.6 million, representing 12.51% of the IRS's proposed adjustment of $380.4 million. The adjustment was allocated among the four tax years as follows:
Federal Income Tax Due: $10.0 million (rounded), computed as $47.6 million × 21%.
Underpayment Interest: Approximately $2.84 million, computed at the applicable federal underpayment rate under IRC § 6621 for each quarter from the original due dates of the TY 2017–2020 returns through the anticipated settlement payment date.
Penalty: $0 — fully abated. Appeals Officer Castañeda accepted PPC's reasonable-cause defense and its contemporaneous transfer pricing documentation as establishing penalty protection under IRC § 6662(e)(3)(B). The fully proposed penalty of approximately $15.98 million was completely eliminated as part of the settlement.
Total Cash Cost: Approximately $12.84 million (tax of $10.0 million plus interest of approximately $2.84 million).
III. ASC 740-10 Framework — Summary of Applicable Standards
This Section provides an overview of the accounting standards applicable to PPC's uncertain tax position analysis. The analysis is governed by ASC Topic 740-10, Income Taxes — Overall, which codifies the provisions formerly set forth in FIN 48, Accounting for Uncertainty in Income Taxes — An Interpretation of FASB Statement No. 109.
A. Two-Step Analysis
ASC 740-10 prescribes a two-step process for the recognition and measurement of uncertain tax positions:
Step 1 — Recognition. Under ASC 740-10-25, a tax position must first be evaluated to determine whether it is "more likely than not" (i.e., a likelihood of greater than 50%) that the position will be sustained upon examination by the relevant taxing authority. This assessment is made based solely on the technical merits of the position, assuming that the taxing authority has full knowledge of all relevant information. If the more-likely-than-not threshold is met, the tax position is recognized for financial statement purposes. If the threshold is not met, no tax benefit is recognized, and the entire tax benefit associated with the position must be reserved.
Step 2 — Measurement. If a tax position meets the Step 1 recognition threshold, the next step is to measure the amount of tax benefit to be recognized in the financial statements. Under ASC 740-10-30, the amount of benefit recognized is the largest amount of tax benefit that has a greater than 50% likelihood of being realized upon ultimate settlement with the taxing authority. This measurement is based on a cumulative probability assessment that considers the range of possible outcomes and their associated probabilities. The measurement analysis takes into account the facts, circumstances, and information available at the reporting date, including the entity's experience with similar positions and the history of outcomes in similar cases.
The two-step analysis under ASC 740-10-25 and ASC 740-10-30 is the framework that Calderwood & Harkness has applied in each of its prior analyses and that is applied in this updated analysis.
B. Reassessment Triggering Events
Under ASC 740-10-25-14, an entity is required to reassess its unrecognized tax benefits at each reporting date based on new information that may bear on the recognition or measurement of the tax positions. Changes in facts and circumstances — including, significantly, the resolution of an examination or audit, the execution of a settlement agreement, or the issuance of a court decision — constitute triggering events that require de-recognition, re-recognition, or re-measurement of affected tax positions.
In the present case, the execution of the Form 906 Closing Agreement on March 29, 2024, constitutes a conclusive and binding resolution of the transfer pricing issues for TY 2017–2020. This is a triggering event of the highest order under ASC 740-10-25-14, as it eliminates all remaining uncertainty with respect to the covered tax positions and fixes the tax liability for those years at a known, determinable amount. Accordingly, the UTP reserve attributable to TY 2017–2020 must be de-recognized and replaced with the known settlement amount.
Separately, the settlement outcome provides relevant evidentiary input for assessing the continuing uncertain tax positions for open and future tax years (TY 2021 forward). While the settlement does not bind the IRS with respect to years not covered by the Closing Agreement, the settlement terms — and in particular the substantial reduction from the IRS's proposed adjustments — are relevant evidence bearing on the measurement of the reserve for continuing positions under ASC 740-10-30.
C. Disclosure Requirements
ASC 740-10-50 sets forth disclosure requirements for uncertain tax positions. These requirements include, among other things:
• A tabular reconciliation of the total amounts of unrecognized tax benefits at the beginning and end of the reporting period, including increases and decreases attributable to current-year positions, prior-year positions, settlements with taxing authorities, and lapses of applicable statutes of limitations.
• Disclosure of the total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.
• A description of the nature of the uncertainty, the events that could cause a material change in the estimate, and the range of reasonably possible changes in the estimate within the next twelve months.
• Disclosure of any significant settlements or resolution events occurring during the reporting period.
PPC must disclose the settlement-related reduction in its FIN 48 reserve in its financial statements for the reporting period that includes March 29, 2024, along with the impact of the reserve release on PPC's effective tax rate for that period. The specific disclosures should be developed in coordination with Crestfield & Associates.
IV. Prior Reserve Positions
A. Initial Reserve (September 2022 Analysis)
In our initial FIN 48 reserve analysis dated September 20, 2022, prepared in connection with PPC's response to the opening of the IRS examination, we analyzed PPC's uncertain tax positions related to its Irish IP-holding structure and the associated intercompany transfer pricing arrangements.
At that time, PPC maintained a pre-examination FIN 48 reserve of $62.4 million under ASC 740-10 related to the Irish IP-holding structure. This reserve reflected a combination of the following identified risks:
(i) The risk that the IRS would challenge the cost-sharing ratios under the CSA, asserting that PBI's share of reasonably anticipated benefits was understated and that PBI should bear a greater proportion of the intangible development costs;
(ii) The risk that the IRS would challenge the 4.5% royalty rate on the legacy IP license, asserting that the arm's-length royalty rate should be substantially higher;
(iii) The risk that the IRS would mount an economic substance or DEMPE-related challenge to PBI's operations, potentially seeking to re-characterize PBI as a mere conduit or shell entity; and
(iv) Accruals for potential underpayment interest that would be owed in the event of any adverse adjustment.
Step 1 Analysis. In our September 2022 analysis, Calderwood & Harkness concluded that PPC's transfer pricing positions — including the CSA cost-sharing ratios, the 4.5% royalty rate, and the PCT payment amount — were "more likely than not" to be sustained on their technical merits if examined by the IRS with full knowledge of all relevant facts. This conclusion was based on the strength of PPC's contemporaneous documentation, the robustness of the supporting economic analyses, PBI's significant and growing operational substance, and the applicable legal authorities under IRC § 482, the Treasury Regulations thereunder, and relevant case law.
Step 2 Analysis. Notwithstanding our favorable Step 1 conclusion, we recommended that PPC maintain a measurement reserve under Step 2 in the amount of $62.4 million. This recommendation reflected the materiality of PPC's transfer pricing positions, the well-known IRS focus on pharmaceutical IP structures involving Irish operations, and the inherent uncertainty in any transfer pricing analysis. The $62.4 million reserve level was determined through a probability-weighted estimation methodology, under which we assessed potential adjustments at various percentages of the intercompany transactions and weighted those potential adjustments by estimated probabilities of occurrence, taking into account settlement and litigation probabilities at various stages of a potential examination and dispute. The resulting reserve represented the difference between the total tax benefit claimed by PPC and the largest amount of tax benefit that was greater than 50% likely to be realized upon ultimate settlement.
B. Post-NOPA Updated Reserve (November 2023 Analysis)
Following the issuance of the NOPA on October 12, 2023 — in which the IRS proposed net adjustments of $380.4 million plus a substantial valuation misstatement penalty of approximately $15.98 million — we updated our FIN 48 analysis in a memorandum dated November 20, 2023.
In our November 2023 analysis, Calderwood & Harkness confirmed that PPC's transfer pricing positions remained "more likely than not" sustainable on their technical merits, notwithstanding the NOPA. Our continued confidence in the Step 1 assessment was based on our detailed analysis of the NOPA, which identified significant analytical weaknesses in the IRS's positions, including:
(a) The IRS's CUT analysis for the royalty rate relied on agreements that were not sufficiently comparable to the PBI legacy license in terms of therapeutic area, stage of development, geographic scope, and exclusivity provisions;
(b) The IRS's CSA cost-sharing ratio analysis was based on an overly simplistic profit-split methodology that failed to account for the relative contributions of PPC and PBI to intangible development;
(c) The IRS's PCT valuation relied on an artificially low WACC of 7.2%, which did not appropriately reflect the risk inherent in early-stage pharmaceutical development; and
(d) The IRS's economic substance challenge was not supported by the factual record, given PBI's substantial and growing operations.
We assessed the $62.4 million reserve as still within the appropriate measurement range under Step 2 because: (i) the NOPA represented the IRS's opening position in the administrative process, not a final determination of PPC's tax liability; (ii) our hazards-of-litigation analysis supported a favorable outcome at the Appeals level, given the significant weaknesses in the IRS's positions; (iii) Whitmore's independent economic analyses were robust and well-supported; and (iv) PBI's economic substance was thoroughly documented and difficult for the IRS to challenge credibly.
Accordingly, no adjustment to the $62.4 million reserve was recommended at that time. This conclusion was consistent with ASC 740-10's guidance that a proposed adjustment by a taxing authority does not, standing alone, necessarily require revision of an entity's UTP reserve absent a change in the entity's assessment of the likely outcomes of the dispute.
We communicated our updated conclusions to Crestfield & Associates LLP (Martin Ogilvy, Engagement Partner) by letter dated November 20, 2023, for use in connection with PPC's year-end 2023 financial statement reporting.
V. Post-Settlement Reserve Analysis
A. Resolution of TY 2017–2020 Positions
1. Impact of the Closing Agreement
The Form 906 Closing Agreement, executed on March 29, 2024, conclusively resolves all transfer pricing issues raised in the IRS examination for Tax Years 2017, 2018, 2019, and 2020. A Form 906 Closing Agreement is a binding contract between the taxpayer and the IRS that, once executed, is final and conclusive as to the matters covered therein. See IRC § 7121(b); Rev. Proc. 68-16, 1968-1 C.B. 770.
The settlement adjustment of $47.6 million represents the final determination of PPC's federal income tax liability for TY 2017–2020 with respect to the transfer pricing issues identified in the NOPA. No further IRS challenge, assessment, adjustment, or reassessment is possible for TY 2017–2020 with respect to these covered matters. The Closing Agreement forecloses any further IRS administrative or judicial action on the settled issues, and PPC has waived its rights to contest the settlement amounts for the covered years.
Because the Closing Agreement constitutes a conclusive and binding resolution of all uncertainty with respect to the TY 2017–2020 transfer pricing positions, the UTP reserve attributable to those years must be fully de-recognized under ASC 740-10-25-14. The previously uncertain tax positions are no longer uncertain — the tax liability for TY 2017–2020 is now a known, determinable amount. Accordingly, the UTP reserve must be replaced with the actual settlement liability.
2. Allocation of Settlement to Prior Reserve
The allocation of the settlement to PPC's prior FIN 48 reserve is as follows:
Pre-settlement UTP reserve: $62.4 million
Settlement adjustment recognized (TY 2017–2020):
• 2017: $11.2 million
• 2018: $12.4 million
• 2019: $12.8 million
• 2020: $11.2 million
• Total settlement adjustment: $47.6 million
Tax cost of settlement: $10.0 million ($47.6M × 21% statutory rate)
Underpayment interest cost: approximately $2.84 million
Penalty: $0 (fully abated)
Total cash cost: approximately $12.84 million
The settlement confirms that PPC's original reserve of $62.4 million was more than sufficient to cover the ultimate resolution of the TY 2017–2020 examination. The actual total income adjustment of $47.6 million (resulting in tax of $10.0 million) was well within the range of outcomes contemplated in our prior probability-weighted analyses, and the total cash cost of $12.84 million (tax plus interest) was substantially below the reserved amount. This outcome validates the reasonableness and conservatism of PPC's reserve methodology throughout the examination period.
3. De-Recognition of TY 2017–2020 Reserve Component
The portion of the $62.4 million UTP reserve attributable to TY 2017–2020 transfer pricing exposure is now fully resolved by the Closing Agreement. Under ASC 740-10-25-14, this portion of the reserve must be de-recognized effective as of the settlement date of March 29, 2024.
The difference between the reserved amount attributable to TY 2017–2020 and the actual settlement amount (i.e., the tax cost of $10.0 million plus interest of $2.84 million) will flow through PPC's income tax provision as a benefit (a reduction in income tax expense) in the reporting period that includes the settlement date. This benefit reflects the favorable resolution of the examination at an amount substantially below the previously reserved level.
The accounting treatment for the de-recognition of the TY 2017–2020 reserve component should be determined in consultation with Crestfield & Associates to ensure appropriate presentation under ASC 740-10 and consistency with PPC's accounting policies.
B. Remaining Reserve — TY 2021 Forward and Continuing Positions
1. Basis for $14.8 Million Remaining Reserve
The adjusted UTP reserve of $14.8 million reflects PPC's continuing uncertain tax positions related to the Irish IP-holding structure for tax years not covered by the Closing Agreement — specifically, TY 2021 and all subsequent tax years for which PPC's federal income tax returns have been or will be filed.
PPC continues to operate the CSA and the legacy IP license with PBI under the same methodologies that were in place during TY 2017–2020. Specifically, PBI continues to make cost-sharing payments based on its share of reasonably anticipated benefits under the CSA, and PBI continues to pay a 4.5% royalty on non-Americas net sales of legacy pre-2012 compounds under the legacy license agreement. The IRS retains the full statutory authority to examine PPC's federal income tax returns for TY 2021 and subsequent years, and no advance pricing agreement, closing agreement, or other pre-filing arrangement covers these periods.
PPC was not enrolled in the IRS Compliance Assurance Process for the years at issue in the examination, and PPC has not yet entered CAP for subsequent tax years. Accordingly, PPC's transfer pricing positions for TY 2021 forward remain subject to potential IRS examination and challenge, and a reserve is warranted under ASC 740-10.
2. Step 1 — Recognition Analysis for Remaining Positions
Calderwood & Harkness's assessment is that PPC's transfer pricing positions for TY 2021 and subsequent tax years remain "more likely than not" sustainable on their technical merits under ASC 740-10-25. This conclusion is based on the following favorable and risk factors.
Favorable Factors:
(a) Settlement Validation. The settlement at 12.51% of the IRS's proposed adjustments provides strong validation of the strength of PPC's transfer pricing positions. While the settlement is not a ruling or precedent, the IRS's willingness to settle at such a substantial discount from its opening position is powerful evidence that PPC's positions are technically sound. This is particularly significant because the settlement followed a thorough examination by an experienced IRS transfer pricing team and a contested Appeals process.
(b) Continued Applicability of Economic Analyses. The economic analyses prepared by Whitmore Valuation Group — including the CUT analysis (14 comparables, IQR of 3.1%–6.8%, median 4.4%), the CPM/TNMM analysis (22 comparables, PBI margins within IQR in all years), and the PCT DCF valuation ($278M–$361M range at 9.8% WACC) — remain applicable to TY 2021 and subsequent years, as the underlying intercompany arrangements have not materially changed. Updated comparable company data will be incorporated in future documentation cycles, but the overall analytical framework remains valid.
(c) Continued Strengthening of PBI's Economic Substance. PBI's operational substance has continued to strengthen since the TY 2017–2020 period. PBI's headcount, regulatory expenditures, governance activities, and DEMPE functions have all continued to grow and deepen, further supporting the arm's-length nature of the intercompany arrangements and PBI's economic substance.
(d) Contemporaneous Documentation. PPC continues to maintain comprehensive contemporaneous transfer pricing documentation for all intercompany transactions, consistent with the requirements of Treasury Regulations § 1.482-7 and § 1.482-4, and the penalty protection standards of IRC § 6662(e)(3)(B). This documentation is prepared on a timely basis by qualified transfer pricing professionals.
(e) Precedential Value of Appeals Outcome. While the Form 906 Closing Agreement does not constitute a binding precedent for future tax years, the Appeals outcome — and in particular the IRS's acceptance of PPC's economic analyses and the full abatement of the penalty — provides valuable precedential context for future examinations. An IRS examiner reviewing PPC's transfer pricing for TY 2021 forward would be aware of the prior settlement and the basis on which it was reached, which may influence the IRS's approach to any future examination.
Risk Factors:
(a) No Binding Precedent from Settlement. The Form 906 Closing Agreement is not a ruling, determination letter, or other form of published guidance. It does not bind the IRS with respect to tax years not covered by the agreement. The IRS is free to take a different position in a future examination of PPC's transfer pricing for TY 2021 and beyond, and there is no legal bar to the IRS proposing larger or different adjustments in a future cycle.
(b) Potential for Different IRS Approaches. The IRS may develop new or different analytical approaches, employ different economists, or apply different interpretive positions in future examination cycles. Changes in IRS personnel, enforcement priorities, or transfer pricing practice areas could result in a more aggressive examination posture.
(c) Evolving Regulatory Landscape. The international tax regulatory landscape is evolving rapidly, particularly with respect to the OECD's Pillar One (reallocation of taxing rights) and Pillar Two (global minimum tax) initiatives. These initiatives may affect the legal and economic framework within which PPC's transfer pricing positions are evaluated, potentially increasing the risk of challenge.
(d) Knowledge Development box Scrutiny. PBI's claims for Ireland's Knowledge Development box ("KDB") rate of 6.25% on qualifying income, which PBI has applied since FY 2016, may attract separate scrutiny from the IRS, Irish Revenue, or both. To the extent the KDB claims are challenged, the effective tax rate on PBI's income could increase, which could in turn affect the IRS's assessment of the transfer pricing arrangements.
Balancing the favorable and risk factors described above, we conclude that PPC's transfer pricing positions for TY 2021 forward meet the "more likely than not" recognition threshold under Step 1 of ASC 740-10-25.
3. Step 2 — Measurement of Remaining Reserve
Having concluded that PPC's positions meet the Step 1 recognition threshold, we turn to the Step 2 measurement analysis under ASC 740-10-30. The $14.8 million remaining reserve reflects the largest amount of tax benefit that is greater than 50% likely to be realized upon ultimate settlement for the continuing positions.
The measurement analysis employs a probability-weighted estimation methodology, consistent with the methodology used in our prior analyses, calibrated by the settlement outcome. Specifically, we have considered the following factors in arriving at the $14.8 million measurement:
Reduced Likelihood of IRS Challenge on Identical Issues. The favorable settlement at 12.51% of proposed adjustments reduces the probability that the IRS will pursue an aggressive examination of PPC's transfer pricing for TY 2021 forward on identical issues. While the settlement does not preclude future examination, it suggests that the IRS recognized significant weakness in its positions and accepted a result far closer to PPC's reported positions than to the IRS's proposed adjustments. We have accordingly reduced the probability weights assigned to adverse outcomes in our measurement model.
Declining Legacy Compound Sales. Non-Americas net sales of legacy pre-2012 compounds have been on a continuing decline trajectory (from $624.1 million in 2020), reflecting the natural product lifecycle of these mature compounds. As legacy compound sales decline, the royalty adjustment exposure — which was the second-largest component of the IRS's proposed adjustments for TY 2017–2020 — diminishes correspondingly. This reduces the potential magnitude of any future IRS challenge to the royalty rate.
Incremental Strengthening of PBI's Substance Profile. PBI's growing headcount, deepening regulatory engagement, expanded governance activities, and enhanced DEMPE functions further reduce the risk of an economic substance challenge in future examination cycles. PBI's evolution since its 2012 inception is a compelling narrative of a maturing operating entity, and the passage of time only strengthens this narrative.
TCJA Provisions. The Tax Cuts and Jobs Act of 2017 introduced several provisions — including the Global Intangible Low-Taxed Income ("GILTI") regime under IRC § 951A and the Base Erosion and Anti-Abuse Tax ("BEAT") under IRC § 59A — that capture a portion of income from controlled foreign corporations, including PBI. To the extent these provisions already bring a portion of PBI's income into the U.S. tax base, the IRS's incentive to pursue § 482 transfer pricing adjustments may be moderated. We have incorporated this factor into our probability weighting.
Potential for Bilateral APA. As discussed in our separate advisory memorandum dated April 20, 2024, PPC is evaluating whether to pursue a bilateral advance pricing agreement with the IRS and Irish Revenue Commissioners for TY 2021 forward. If an APA is obtained, it would provide prospective certainty for the covered period and could allow for a further reduction or elimination of the remaining UTP reserve. We have not assumed that an APA will be obtained, but we note this as a potential future development.
Based on the foregoing analysis, the $14.8 million measurement is, in our assessment, the appropriate reserve level under ASC 740-10-30. This amount represents the difference between the total tax benefit claimed by PPC on its transfer pricing positions for TY 2021 forward and the largest amount of that tax benefit that has a greater than 50% probability of being realized upon ultimate resolution. The measurement is net of the favorable evidentiary weight of the settlement outcome.
C. Reconciliation of Reserve Adjustment
The reconciliation of PPC's UTP reserve from the pre-settlement level to the post-settlement level is as follows:
The $47.6 million net reserve reduction equals the settlement adjustment amount. This result reflects the fact that the portion of the reserve attributable to TY 2017–2020 was approximately equal to the total pre-settlement reserve ($62.4 million) minus the continuing-position reserve ($14.8 million). In other words, the original $62.4 million reserve was composed of approximately $47.6 million attributable to TY 2017–2020 exposure and approximately $14.8 million attributable to continuing exposure for TY 2021 forward.
Financial Statement Impact. The $47.6 million reserve reduction will result in a net benefit to PPC's income tax provision in the reporting period ending on or after March 29, 2024. This benefit will be partially offset by the underpayment interest cost of approximately $2.84 million and any applicable state income tax consequences (discussed in Section VIII below). The net after-tax impact on PPC's financial statements should be determined in consultation with Crestfield & Associates, taking into account the specific timing and presentation requirements under ASC 740-10.
VI. Interest and Penalty Considerations
A. Interest
The settlement requires PPC to pay estimated underpayment interest of approximately $2.84 million. This interest is computed at the applicable federal underpayment rate under IRC § 6621 for each calendar quarter from the original due dates of PPC's federal income tax returns for TY 2017 through TY 2020 through the anticipated settlement payment date. The applicable underpayment rate is the federal short-term rate plus three percentage points, compounded daily for the period of the underpayment.
The IRS will compute the exact interest amount at the time of assessment based on the date of PPC's payment. The $2.84 million estimate is based on our computation using the applicable quarterly underpayment rates published by the IRS for each quarter during the relevant period, applied to the annual tax deficiency for each year from the original return due date through an assumed payment date of April 30, 2024.
Under IRC § 163(a), underpayment interest paid to the IRS is generally deductible for federal income tax purposes, subject to applicable limitations including the business interest deduction limitation under IRC § 163(j). PPC should confirm with Crestfield & Associates the deductibility of the interest payment in the context of PPC's overall § 163(j) computation.
The interest accrual should be reflected in PPC's financial statements for the reporting period that includes the settlement date, in accordance with ASC 740-10 and PPC's accounting policies for interest on tax deficiencies.
B. Penalty Abatement
The IRC § 6662(e) penalty for substantial valuation misstatement was fully abated as part of the settlement. The proposed penalty had been calculated at approximately $15.98 million, based on the following computation:
Total proposed adjustment: $380.4 million Tax on adjustment at 21%: $79.88 million Penalty rate (20% substantial valuation misstatement): × 20% Proposed penalty: approximately $15.98 million
The full abatement of this penalty was a significant component of the favorable settlement outcome. Appeals Officer Castañeda accepted PPC's reasonable-cause defense under IRC § 6664(c) and, more specifically, accepted that PPC's contemporaneous transfer pricing documentation satisfied the requirements for penalty protection under IRC § 6662(e)(3)(B). The penalty protection provision of § 6662(e)(3)(B) provides that the substantial valuation misstatement penalty does not apply to any portion of an underpayment if the taxpayer establishes that the reported price or value of the relevant property or services was determined in accordance with a specified transfer pricing methodology, as set forth in the applicable regulations, and that the taxpayer had reasonable cause for its determination and acted in good faith. PPC's contemporaneous documentation, prepared by Crestfield & Associates, satisfied both prongs of this standard.
Reserve Implications. No reserve for penalties is required for TY 2017–2020, as the penalty has been fully resolved at $0 pursuant to the Closing Agreement.
For TY 2021 and subsequent tax years, PPC's continuing maintenance of comprehensive contemporaneous transfer pricing documentation provides ongoing penalty protection under IRC § 6662(e)(3)(B). So long as PPC continues to prepare timely documentation that meets the regulatory requirements, the risk of a substantial valuation misstatement penalty remains low. Accordingly, no incremental penalty reserve is recommended for TY 2021 forward. However, this conclusion is contingent on PPC's continued compliance with the documentation requirements, and any lapse or deficiency in documentation could warrant the establishment of a penalty reserve.
VII. Impact on Financial Statements and Reporting
A. Income Tax Provision
The settlement-related reserve release will generate a net benefit to PPC's income tax provision in the reporting period that includes the settlement date (March 29, 2024). The benefit is quantified as follows:
Gross reserve release (net reduction in UTP reserve): $47.6 million Less: Interest expense accrual: ($2.84 million) Net pre-tax benefit: $44.76 million (subject to adjustment for state tax effects and other items)
The reserve release will reduce PPC's effective tax rate for the reporting period in which it is recognized. Given PPC's pre-tax income level (approximately $1.47 billion in FY 2020), the reserve release will have a meaningful but not transformative impact on the effective tax rate. The precise effective tax rate impact will depend on PPC's pre-tax income for the applicable reporting period and should be computed by Crestfield & Associates in connection with the preparation of PPC's tax provision.
B. Balance Sheet Impact
The settlement will result in the following balance sheet changes: